Adult-Onset Type 1 Diabetes: Current Understanding and Challenges
- PMID: 34670785
- PMCID: PMC8546280
- DOI: 10.2337/dc21-0770
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges
Abstract
Recent epidemiological data have shown that more than half of all new cases of type 1 diabetes occur in adults. Key genetic, immune, and metabolic differences exist between adult- and childhood-onset type 1 diabetes, many of which are not well understood. A substantial risk of misclassification of diabetes type can result. Notably, some adults with type 1 diabetes may not require insulin at diagnosis, their clinical disease can masquerade as type 2 diabetes, and the consequent misclassification may result in inappropriate treatment. In response to this important issue, JDRF convened a workshop of international experts in November 2019. Here, we summarize the current understanding and unanswered questions in the field based on those discussions, highlighting epidemiology and immunogenetic and metabolic characteristics of adult-onset type 1 diabetes as well as disease-associated comorbidities and psychosocial challenges. In adult-onset, as compared with childhood-onset, type 1 diabetes, HLA-associated risk is lower, with more protective genotypes and lower genetic risk scores; multiple diabetes-associated autoantibodies are decreased, though GADA remains dominant. Before diagnosis, those with autoantibodies progress more slowly, and at diagnosis, serum C-peptide is higher in adults than children, with ketoacidosis being less frequent. Tools to distinguish types of diabetes are discussed, including body phenotype, clinical course, family history, autoantibodies, comorbidities, and C-peptide. By providing this perspective, we aim to improve the management of adults presenting with type 1 diabetes.
© 2021 by the American Diabetes Association.
Figures
References
-
- Thunander M, Petersson C, Jonzon K, et al. . Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008;82:247–255 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK127308/DK/NIDDK NIH HHS/United States
- R21 DK119800/DK/NIDDK NIH HHS/United States
- I01 BX001733/BX/BLRD VA/United States
- U01 DK098246/DK/NIDDK NIH HHS/United States
- I01 CX001737/CX/CSRD VA/United States
- R21 DK099716/DK/NIDDK NIH HHS/United States
- UL1 TR002378/TR/NCATS NIH HHS/United States
- R01 DK138335/DK/NIDDK NIH HHS/United States
- R18 DK066204/DK/NIDDK NIH HHS/United States
- I01 BX005831/BX/BLRD VA/United States
- U01 DK127786/DK/NIDDK NIH HHS/United States
- R03 AI133172/AI/NIAID NIH HHS/United States
- P30 DK097512/DK/NIDDK NIH HHS/United States
- CS-2015-15-018/DH_/Department of Health/United Kingdom
- R01 DK093954/DK/NIDDK NIH HHS/United States
- U34 DK091958/DK/NIDDK NIH HHS/United States
- R21 AI156161/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
